JP2017036288A5 - - Google Patents

Download PDF

Info

Publication number
JP2017036288A5
JP2017036288A5 JP2016175431A JP2016175431A JP2017036288A5 JP 2017036288 A5 JP2017036288 A5 JP 2017036288A5 JP 2016175431 A JP2016175431 A JP 2016175431A JP 2016175431 A JP2016175431 A JP 2016175431A JP 2017036288 A5 JP2017036288 A5 JP 2017036288A5
Authority
JP
Japan
Prior art keywords
inhibitor
subject
administered
use according
jak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016175431A
Other languages
English (en)
Japanese (ja)
Other versions
JP6375345B2 (ja
JP2017036288A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017036288A publication Critical patent/JP2017036288A/ja
Publication of JP2017036288A5 publication Critical patent/JP2017036288A5/ja
Application granted granted Critical
Publication of JP6375345B2 publication Critical patent/JP6375345B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016175431A 2011-04-28 2016-09-08 Ｈｓｐ９０併用療法 Expired - Fee Related JP6375345B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480198P 2011-04-28 2011-04-28
US61/480,198 2011-04-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014508165A Division JP6363502B2 (ja) 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018106047A Division JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Publications (3)

Publication Number Publication Date
JP2017036288A JP2017036288A (ja) 2017-02-16
JP2017036288A5 true JP2017036288A5 (enExample) 2017-07-13
JP6375345B2 JP6375345B2 (ja) 2018-08-15

Family

ID=47073116

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014508165A Expired - Fee Related JP6363502B2 (ja) 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法
JP2016175431A Expired - Fee Related JP6375345B2 (ja) 2011-04-28 2016-09-08 Ｈｓｐ９０併用療法
JP2018106047A Withdrawn JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014508165A Expired - Fee Related JP6363502B2 (ja) 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018106047A Withdrawn JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Country Status (12)

Country Link
US (2) US20140315929A1 (enExample)
EP (1) EP2701747A4 (enExample)
JP (3) JP6363502B2 (enExample)
KR (2) KR102196424B1 (enExample)
CN (2) CN103998935B (enExample)
AU (3) AU2012249322B2 (enExample)
BR (1) BR112013027448A2 (enExample)
CA (1) CA2833390A1 (enExample)
EA (1) EA201391587A1 (enExample)
MX (1) MX2013012183A (enExample)
NZ (1) NZ618062A (enExample)
WO (1) WO2012149493A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2624982T3 (es) 2011-07-08 2017-07-18 Sloan-Kettering Institute For Cancer Research Usos de inhibidores etiquetados HSP90
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US10071130B2 (en) 2013-12-12 2018-09-11 The University Of Chicago Methods and compositions related to Hsp90 inhibitors and breast cancer
MX2016008418A (es) 2013-12-23 2017-01-11 Memorial Sloan Kettering Cancer Center Metodos y reactivos para el radiomarcaje.
EP3137117A4 (en) * 2014-05-02 2018-04-04 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondria for cancer therapy
EP3194975A4 (en) 2014-09-17 2018-05-02 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
WO2016065075A1 (en) 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
EP3283650A4 (en) * 2015-04-13 2019-04-10 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIAL-DERIVED CHARACTERIZATION, DIAGNOSTICS AND THERAPEUTIC FOR DISEASES RELATED TO FUNCTIONAL ELEMENTS
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
CN106265660B (zh) * 2015-05-21 2019-08-02 中国科学院合肥物质科学研究院 A674563在携带flt3突变型基因的急性白血病中的用途
CN106349180B (zh) * 2015-07-14 2020-05-19 上海翰森生物医药科技有限公司 4,5-二苯基异噁唑衍生物及其制备方法和应用
MX2019001467A (es) * 2016-08-03 2019-10-02 Remd Biotherapeutics Inc Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
CA3052594A1 (en) * 2017-02-03 2018-08-09 AI Therapeutics, Inc. Methods for treating cancer using hsp90 inhibitors
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
US11377447B2 (en) 2017-06-20 2022-07-05 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
CN109554343B (zh) * 2018-12-29 2022-04-19 吉林大学 一种适于神经元粘附与存活的涂层材料及制备方法
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
CN111467472B (zh) * 2020-04-21 2020-12-25 南京中医药大学 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用
WO2021252490A2 (en) * 2020-06-11 2021-12-16 The Children's Medical Center Corporation Use of heat shock protein inhibitors for the treatment of neurodevelopmental disorders
US11389431B2 (en) 2020-09-09 2022-07-19 Social Profit Network Methods and compositions for delivery of biotin to mitochondria
AU2021362975A1 (en) * 2020-10-14 2023-05-25 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
JP5721949B2 (ja) * 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
CA2677651A1 (en) * 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2008114812A1 (ja) * 2007-03-19 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Jak阻害剤
CN103479604B (zh) * 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
US20100310563A1 (en) * 2007-11-30 2010-12-09 Bumm Thomas G P Methods for treating induced cellular proliferative disorders
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2734428A1 (en) * 2008-08-18 2010-02-25 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Susceptibility to hsp90-inhibitors
BRPI0922301A2 (pt) * 2008-11-28 2019-02-26 Novartis Ag combinações de inibidor de hsp90
US8669289B2 (en) * 2009-04-24 2014-03-11 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
CA2765534C (en) * 2009-06-15 2018-09-18 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
MX380504B (es) * 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
EP2714038A1 (en) * 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
JP2023506532A5 (enExample)
FI3265084T3 (fi) Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita
JP2016163571A5 (enExample)
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2017057230A5 (enExample)
NO20092585L (no) Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner
JP2014530874A5 (enExample)
ME02400B (me) Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
ES2527544T1 (es) Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2006508953A5 (enExample)
CN110891953A (zh) 吡咯并三嗪类衍生物、其制备方法及其用途
AR062453A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
JP2020529995A5 (enExample)
JP2021535107A5 (enExample)
FI3661510T3 (fi) Menetelmiä käyttäytymismuutosten hoitamiseksi
FI3600276T3 (fi) Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa
JP2022532038A5 (enExample)
JP2023531930A5 (enExample)
JP2019530711A5 (enExample)
WO2023043830A1 (en) Combination therapies to treat viral infections
JP2019520407A5 (enExample)
CN109689657A (zh) 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
HRP20110365T1 (hr) Kombinacija azd2171 i pemetrekseda